Brief: Ovid Therapeutics Announces New Ov329 Data And Indication Expansion, Phase 1 Clearance For Ov4071, And Reports Fourth Quarter And Full Year 2025 Financial Results
18/03/2026 11:18
March 18 (Reuters) - Ovid Therapeutics Inc OVID.O: OVID THERAPEUTICS ANNOUNCES NEW OV329 DATA AND INDICATION EXPANSION, PHASE 1 CLEARANCE FOR OV4071, AND REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS OVID THERAPEUTICS INC - REPORTS $90.4 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2025 Source text: ID:nGNX3lYXWH Further company coverage: OVID.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors